access to care 83–4
acute stress disorder (ASD) 1, 17–18
cognitive behaviour therapy (CBT) 174
early intervention 180–1
epidemiology 66–7
adjustment disorders (ADs) 1, 19, 43
adrenocorticotrophic hormone (ACTH) 99
age as a risk factor for PTSD 62
agoraphobia, post-traumatic 187
alcohol abuse 64–5
allopregnanolone (ALLO) 98–9
allostatic stress hypothesis 120, 139–41, 143–4
γ-amino butyric acid (GABA) 94, 95
amygdala
basolateral nucleus (BLA) 91–2, 94, 95–6
central nucleus (CE) 91–2
fear response 96–7
monoaminergic modulation 94–5
structural alterations in PTSD 107
traumatic stimulus response 2
analgesia, stress-induced 2
anger 190
anterior cingulate cortex (ACC)
connectivity 118
structural abnormalities in PTSD
107–8, 117
anterior cingulate gyrus 2
anxiety disorders not otherwise specified (NOS) 6
archicortical system 105, 116, 119
avoidance behaviours 2
external reminders (DSM-IV-TR Criterion C2) 13
internal reminders (DSM-IV-TR Criterion C1) 13
avoidance, excessive 190
basolateral nucleus of the amygdala (BLA) 91–2, 94, 95–6
fear response 96–7
BDNF gene 102, 103
brain imaging of PTSD
functional 108–15
structural 105–8
catastrophic thinking 190–1
central nucleus (CE) of the amygdala 91–2
Child Psychosocial Distress Screener (CPDS) 249
children
cognitive processing therapy (CPT) 177
individual and family therapy 252–3
mental health and psychosocial support (MHPSS)
classroom-based intervention (CBI) 251–2
parental support 252
peace education and conflict resolution at schools 246
psychological interventions 203–4
CBT 177
classroom-based intervention (CBI) 251–2
clinical evaluation of PTSD 38–40, 41
cognitive behaviour therapies (CBTs) 12–14, 172–3
historical overview 171–2
mechanisms 173–4
cognitive processing therapy (CPT) 173
evidence
adults 175–7
children 177
combat exhaustion 49
communities in disasters 228
community-based rehabilitation (CBR) 223
community empowerment 244–5, 268–9
comorbidity
complicated grief 186–7
depression 185
generalised anxiety disorder (GAD) 186
mild traumatic brain injury (MTBI) 188–9
post-traumatic agoraphobia and panic disorder 187
psychiatric 64–5
substance-use disorder 188
compensation 244, 249
complementary and alternative medicine (CAM) 233
complex PTSD 20–2
complicated grief 186–7
conditioned stress responses 97
allopregnanolone/pregnanolone (ALLO) 98–9
cortisol 100–1
dehydroepiandrosterone (DHEA) 99–100
neuropeptide Y (NPY) 97–8
conditioning 2
context of healing 217–18
contraindications for trauma-focused therapy 190–1
cortisol 100–1
counter-conditioning 172
course of PTSD 65–6
Critical Incident Stress Debriefing (CISD) 178
cultural aspects of public mental health interventions 237–8
cultural factors in PTSD 22–3
D-cycloserine (DCS) 165–6, 168
cytosine-guanine dinucleotide repeats (CpG) 102–3
Da Costa’s syndrome 3
dehydroepiandrosterone (DHEA) 99–100
depression 185, 191
development and PTSD 23–4
dinucleotide methyltransferase (DNMT) 103
disaster public mental health (DPMH) model 221–3, 275–7
Phase 1 – pre-programme and cyclical assessment 226–9
Phase 2 – defining priorities 230
Phase 3 – interventions 239–42
disasters 218–19
disorders of extreme stress not otherwise specified (DESNOS) 20–2
dissociative disorder not otherwise specified (DDNOS) 234
dissociative flashbacks (DSM-IV-TR Criterion B3) 12
dissociative identity disorder (DID) 234
dissociative subtype of PTSD 22
dopamine (DA) 92, 93, 94
dorsal striatum 2
DSM-III diagnostic criteria 35–6, 49–50
DSM-IV-TR diagnostic criteria 36–7
Criterion A1 4, 5–10
Criterion A2 8–10
Criterion B 12–13
Criterion C 13–14
Criterion D 14–15
Criterion E 15–16
Criterion F 16
factor structure 11
summary 16–17
DSM-5 diagnostic criteria 37, 42–5
emotional arousal following reminders (DSM-IV-TR Criterion B4) 12
emotional numbing 2
emotional processing theory 2
Epidemiologic Catchment Area (ECA) 51
epidemiological research 75–6, 78
challenges 76–7
future horizons 77–8
epidemiology 49–50, 68
acute stress disorder (ASD) 66–7
course of PTSD 65–6
gender-based 82, 84
access to care 83–4
prevalence of PTSD 82–3
refugee status 83
psychiatric comorbidty 64–5
role in DPMH model 231–2
sociodemographic risk factors 62
age 62
ethnicity 63
gender 62
marital status 63
race 63
socioeconomic education 64
socioeconomic status 63–4
trauma exposure in general population
50–1, 61
Australia 55, 61
Europe 53–5, 59–61
Latin America 53, 58
Lebanon 55, 61
North America 51–8
epigenetic contributions to PTSD risk 102–3
therapeutic aspects 103–4
ethnicity as a risk factor for PTSD 63
excessive avoidance 190
exposure therapy 171, 172, 211–12
extinction 95–6, 117
eye-movement desensitisation and reprocessing (EMDR) 174–5, 181–2
fear (DSM-IV-TR Criterion A2) 8–10
fear conditioning 2
fear conditioning and extinction 96–7, 142–4
monoaminergic modulation
amygdala 94–5
prefrontal cortex (PFC) 93–4
species-specific defence response
(SSDR) 92–3
unconditioned defence responses 91–2
fluoxetine 151
forensic evaluation of PTSD 40–1
gender as a risk factor for PTSD 62, 82, 84
access to care 83–4
prevalence 82–3
refugee status 83
generalised anxiety disorder (GAD) 65, 186
 genetic contributions to PTSD risk 101–2
helplessness (DSM-IV-TR Criterion A2) 8–10
hippocampus 2
reduced volume in PTSD 105–7
historical perspective 3–4
horror (DSM-IV-TR Criterion A2) 8–10
humanitarian relief operations 243
hyperarousal 2
hyperarousal subtype of PTSD 22
hypervigilance 2
hypothalamic-pituitary-adrenal (HPA) axis 144
hypothalamus 2
hysteria 234
idiom of distress 233–4
Institute of Medicine (IOM) 152, 153, 167–8
insula 2
internally displaced persons (IDPs) 264
International Classification of Diseases (ICD) 50
interventions for public mental health 254
nongovernmental organisations (NGOs) coordinating public mental health 239–42
primary prevention 240
primary prevention, community-focused 244–247
primary prevention, family and individual 248–249
interventions for public mental health (cont.)
primary prevention, societal 242
secondary prevention 241
secondary prevention, community-focused 274
secondary prevention, family and individual 249–253
secondary prevention, societal 243–244
tertiary prevention 241, 254

key informant (KI) interviews 229
kindling hypothesis 120, 143

locus ceruleus (LC) 2, 92
low- and middle-income countries (LAMICs) 219
suitability of MHPSS model 263–5
treatment gaps in conflicts and disasters 220–1
treatment needs and treatment gaps 219–20

major depressive disorder (MDD) 64
marital status as a risk factor for PTSD 63
medial prefrontal cortex 2
mental health and psychosocial support (MHPSS) 225, 226
children 251–252
integrative approach to recovery 266–271
mental health 253
psychosocial support counselling 250–1
self-help groups 250
suitability for LAMICs 263–5
N-methyl-D-aspartate (NMDA) 95
mild traumatic brain injury (MTBI) 188–9
mirtazepine 152
monoaminergic modulation amygdala 94–5
prefrontal cortex (PFC) 93–4
motor-vehicle accident (MVA) survivors 67

National Institute for Clinical Excellence (NICE) 152–3
neurobiology 120–1
background 89–90
complexity and heterogeneity 90–1
fear conditioning and extinction 91, 96–7
conditioned stress 95–6
monoaminergic modulation 93–5
species-specific defence response (SSDR) 92–3
unconditioned defence responses 91–2
modulation of conditioned stress responses 97
allopregnanolone/pregnanolone (ALLO) 98–9
cortisol 100–1
dehydroepiandrosterone (DHEA) 99–100
neuropeptide Y (NPY) 97–8
structural and functional neuroanatomy
conceptual framework 104–5
connectivity patterns 118–20
functional brain imaging of PTSD 108–15
structural brain imaging of PTSD 105–8
synthesis of animal and human studies 116–18
neurocirculatory asthemia 3
neuropeptide Y (NPY) 97–8
gene 101, 103
nongovernmental organisations (NGOs)
coordinating public mental health 239–42
norepinephrine (NE; noradrenaline) 93, 94
nostalgia 3
nucleus accumbens (NA) 92
numbing symptom 11
ongoing stressors 191
orbitofrontal cortex 2
paleocortical system 105, 116
panic disorder 187
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>parahippocampal subdivision of the brain</td>
<td>104–5</td>
</tr>
<tr>
<td>parapiriform subdivision of the brain</td>
<td>104–5</td>
</tr>
<tr>
<td>partial PTSD</td>
<td>20</td>
</tr>
<tr>
<td>Pavlovian fear conditioning</td>
<td>2</td>
</tr>
<tr>
<td>pharmacotherapy</td>
<td>149, 158–9</td>
</tr>
<tr>
<td>critical view</td>
<td>163</td>
</tr>
<tr>
<td>development</td>
<td>149–52</td>
</tr>
<tr>
<td>evidence</td>
<td>152–4</td>
</tr>
<tr>
<td>key issues</td>
<td>154</td>
</tr>
<tr>
<td>comparison with psychotherapy</td>
<td>157</td>
</tr>
<tr>
<td>dose and duration</td>
<td>155</td>
</tr>
<tr>
<td>optimal SSRI</td>
<td>154–5</td>
</tr>
<tr>
<td>prophylaxis of PTSD</td>
<td>158</td>
</tr>
<tr>
<td>PTSD subtypes and spectrum</td>
<td>155–7</td>
</tr>
<tr>
<td>treatment-refractory PTSD</td>
<td>157–8</td>
</tr>
<tr>
<td>need for new agents</td>
<td>167–8</td>
</tr>
<tr>
<td>shortcomings</td>
<td>164–6</td>
</tr>
<tr>
<td>physiological arousal following reminders (DSM-IV-TR Criterion B5)</td>
<td>12</td>
</tr>
<tr>
<td>political violence</td>
<td>218–19</td>
</tr>
<tr>
<td>possession trance</td>
<td>234</td>
</tr>
<tr>
<td>post-traumatic agoraphobia</td>
<td>187</td>
</tr>
<tr>
<td>post-traumatic stress disorder (PTSD)</td>
<td>complex 20–2</td>
</tr>
<tr>
<td>cross-cultural factors</td>
<td>22–3</td>
</tr>
<tr>
<td>developmental issues</td>
<td>23–4</td>
</tr>
<tr>
<td>disorders of extreme stress not otherwise specified (DESNOS)</td>
<td>20–2</td>
</tr>
<tr>
<td>features</td>
<td>1–2</td>
</tr>
<tr>
<td>partial</td>
<td>20</td>
</tr>
<tr>
<td>redefining for DSM-5</td>
<td>42–5</td>
</tr>
<tr>
<td>subsyndromal</td>
<td>20</td>
</tr>
<tr>
<td>subtypes</td>
<td>22</td>
</tr>
<tr>
<td>treatment-refractory</td>
<td>157–8</td>
</tr>
<tr>
<td>prefrontal cortex (PFC)</td>
<td>92</td>
</tr>
<tr>
<td>extinction</td>
<td>95–6</td>
</tr>
<tr>
<td>fear response</td>
<td>96–7</td>
</tr>
<tr>
<td>hypoactivation in PTSD</td>
<td>117</td>
</tr>
<tr>
<td>monoaminergic modulation</td>
<td>93–4</td>
</tr>
<tr>
<td>pregnanolone (ALLO)</td>
<td>98–9</td>
</tr>
<tr>
<td>preventing mental ill-health following trauma</td>
<td>79–81, 239–242</td>
</tr>
<tr>
<td>prisoners of war</td>
<td>40–1</td>
</tr>
<tr>
<td>prophylaxis of PTSD</td>
<td>158</td>
</tr>
<tr>
<td>early intervention for all trauma-exposed individuals</td>
<td>178–80</td>
</tr>
<tr>
<td>early intervention for PTSD/ASD</td>
<td>180–1</td>
</tr>
<tr>
<td>eye-movement desensitisation and reprocessing (EMDR)</td>
<td>181–2</td>
</tr>
<tr>
<td>prospective studies</td>
<td>144–5</td>
</tr>
<tr>
<td>psychiatric comorbidity</td>
<td>64–5</td>
</tr>
<tr>
<td>Psychological First Aid (PFA)</td>
<td>180</td>
</tr>
<tr>
<td>psychological interventions</td>
<td>171, 191–2</td>
</tr>
<tr>
<td>children</td>
<td>203–4</td>
</tr>
<tr>
<td>clinical guidelines</td>
<td>182–5</td>
</tr>
<tr>
<td>comorbidity</td>
<td>185–189</td>
</tr>
<tr>
<td>contraindications</td>
<td>190–191</td>
</tr>
<tr>
<td>evidence</td>
<td>175</td>
</tr>
<tr>
<td>CBT in adults</td>
<td>175–7</td>
</tr>
<tr>
<td>CBT in children</td>
<td>177</td>
</tr>
<tr>
<td>prophylactic approaches</td>
<td>177–82</td>
</tr>
<tr>
<td>exposure therapy</td>
<td>211–12</td>
</tr>
<tr>
<td>further evidence needed</td>
<td>208–10</td>
</tr>
<tr>
<td>Hispanics</td>
<td>205–7</td>
</tr>
<tr>
<td>historical overview</td>
<td>171–2</td>
</tr>
<tr>
<td>major interventions</td>
<td></td>
</tr>
<tr>
<td>cognitive behaviour therapy (CBT)</td>
<td>172–4</td>
</tr>
<tr>
<td>eye-movement desensitisation and reprocessing (EMDR)</td>
<td>174–5</td>
</tr>
<tr>
<td>psychotherapy compared with pharmacotherapy</td>
<td>157</td>
</tr>
<tr>
<td>public mental health issues</td>
<td></td>
</tr>
<tr>
<td>background</td>
<td>221</td>
</tr>
<tr>
<td>political violence, war and disaster</td>
<td>218–19</td>
</tr>
<tr>
<td>therapist, context and technique</td>
<td>217–18</td>
</tr>
<tr>
<td>treatment gaps in LAMICs</td>
<td>220–1</td>
</tr>
<tr>
<td>treatment needs and treatment gaps</td>
<td>219–20</td>
</tr>
<tr>
<td>core concepts and definitions</td>
<td>225–6</td>
</tr>
<tr>
<td>scope</td>
<td>221–3</td>
</tr>
<tr>
<td>basic principles</td>
<td>224</td>
</tr>
<tr>
<td>quality of interventions</td>
<td>234, 243–4</td>
</tr>
</tbody>
</table>
race as a risk factor for PTSD 63
railway spine 3
raphe nuclei 92
recurrent intrusive recollections
(DSM-IV-TR Criterion B1) 12
refugee status and PTSD 83
reparation 244, 249
repatriation, voluntary 244
reptilian brain 104–5
risk factors for PTSD 39–40
sociodemographic 62
age 62
ethnicity 63
gender 62
marital status 63
race 63
socioeconomic education 64
socioeconomic status 63–4

selective serotonin reuptake inhibitors
(SSRIs) 150–1, 152–3
dose and duration 155
optimal for PTSD 154–5
serotonin 93
serotonin noradrenaline reuptake inhibitors (SNRIs) 154–5
severe depression 191
shell shock 3, 49
single nucleotide polymorphism (SNP) 102
socioeconomic education as a risk factor for PTSD 64
socioeconomic status as a risk factor for PTSD 63–4
soldier’s heart 3, 49
species-specific defence response (SSDR) 92–3
stress-induced analgesia 2
stress-inoculation training 171
stressors and mental illness 1, 5–7
substance-use disorder 188
subs syndromal PTSD 20
subsystem clash hypothesis 120
suicide risk 191
systematic desensitisation 171, 172

technique selection 217–18
thalamus 2
therapist, importance of 217–18
timing of interventions 234
trauma-related borderline personality disorder 234
traumascape 226
traumatic exposure (DSM-IV-TR Criterion A1) 4–7, 9–10
usefulness of 7–8
traumatic neurosis 3, 49
traumatic nightmares (DSM-IV-TR Criterion B2) 12
traumatic shock 49
truncated response hypothesis 120
two-factor theory 2
unconditioned stimuli (US) and the fear response 91–2

valproic acid 103
venlafaxine 151
ventral striatum 2
ventral tegmental area (VTA) 92
violence, political 218–19
volume of interventions 234

war 218–19
war psychoneurosis 49
World Health Organization (WHO) 50
categories of violence 218